| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $85.9M | +6.3% |
| SG&A Expense | $33.8M | +42.2% |
| Operating Income | -$119.7M | -14.4% |
| Income Tax | $0 | -100.0% |
| Net Income | -$103.7M | -16.5% |
| EPS (Basic) | -$1.83 | +3.2% |
| EPS (Diluted) | -$1.83 | +3.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $98.9M | -20.3% |
| Short-term Investments | $363.7M | +92.1% |
| Current Assets | $474.9M | +49.3% |
| Total Assets | $476.2M | +46.2% |
| Current Liabilities | $16.6M | +4.1% |
| Total Liabilities | $16.6M | +4.1% |
| Stockholders' Equity | $459.6M | +48.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$70.3M | +3.9% |
| Investing Cash Flow | -$173.8M | -382.9% |
| Financing Cash Flow | $218.9M | +64.4% |